VIA EDGAR
June 3, 2019
United States Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4561
100 F Street, N.E.
Washington, D.C. 20549
Attention: Sonia Bednarowski
Re: | Orchard Therapeutics plc |
Acceleration Request for Registration Statement on Form F-1
File No. 333-231916
Dear Ms. Bednarowski:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the Act), Orchard Therapeutics plc (the Company) hereby requests that the effective date of the above-referenced registration statement (the Registration Statement) be accelerated to June 5, 2019, at 4:50 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Michael Bison at (617) 570-1933. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the Commission) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Michael Bison, by facsimile to (617) 321-4370.
If you have any questions regarding this request, please contact Michael Bison of Goodwin Procter LLP at (617) 570-1933.
Sincerely, |
Orchard Therapeutics plc |
/s/ Mark Rothera |
Mark Rothera President and Chief Executive Officer |
cc: | John Ilett, Orchard Therapeutics plc |
Frank Thomas, Orchard Therapeutics plc
Michael H. Bison, Esq., Goodwin Procter LLP
Courtney Hetrick, Esq., Goodwin Procter LLP